BridGene Biosciences Secures $28 Million to Boost Clinical Trials and Expand Its Drug Development Pipeline BridGene Biosciences has successfully raised $28 million in a Series B+ funding round, aimed at advancing its cancer drug BGC-515 and its innovative drug development approach.

BridGene Biosciences Secures $28 Million to Boost Clinical Trials and Expand Its Drug Development Pipeline #United_States #San_Jose #BridGene_Biosciences #Bayland_Capital #BGC-515